The bacterial strains, plasmids and primers used in this study are listed in Supplementary Table S1, Table S2 and Table S3, respectively. All bacterial strains were grown on Luria-Bertani (LB) plates or in LB broth. All NDM-1-positive strains were originated from our previous studies [17] . E. cloacae 20710 and E. cloacae 20712 were provided by Dr. Yonghong Xiao at Zhejiang University [18] . A. baumannii 21 was provided by Dr. Zhimin Guo at the First Hospital of Jilin University.
The full gene sequences of blaIMP-1, blaVIM-1, blaKPC-2 and blaOXA-48 were synthesized by GeneScript (Nanjing, China) and were inserted into pET28a or pETSUMO for protein expression.
The FDA-approved drug library was purchased from ApexBio Technology (Cat#L1021, Houston, TX, USA).
Dexrazoxane,
embelin, CAN and NDGA were dissolved in
DMSO (Sigma-Aldrich, St. Louis, MO, USA).
Meropenem,
amoxicillin,
ciprofloxacin,
imipenem,
erythromycin,
chloramphenicol,
tetracycline and
gentamicin were obtained from Dalian Meilun Biotechnology Co., Ltd. (Dalian, China).
Guo Y., Liu H., Yang M., Ding R., Gao Y., Wang H., Deng X., Wang J., Feng H., & Qiu J. (2022). Novel MBLs inhibitors screened from FDA-approved drug library restore the susceptibility of carbapenems to NDM-1-harbouring bacteria.